Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Skin of Color Savvy: The Art and Science of Treating Patients of Color

 closed its 8th Annual Media Day with a fast-moving mix of clinical insights, myth-busting commentary, and evidence-driven guidance during a year when misinformation continues to spread across consumer channels. The virtual press-conference format, now a signature of this event, drew viewers seeking expert perspective on emerging conversations linked to dermatology, science, health equity, aesthetic medicine, and everyday lifestyle choices affecting patients with richly pigmented skin.

Since 2015, SOCS Media Day has grown into a high-value newsroom resource known for exclusive access to leading dermatologists and early looks at new research. The 2025 program, held on November 18, assembled eight authorities who delivered focused sessions on trends shaping public discussions and clinical decision-making.

Brittany Oliver, MD, and Dhaval G. Bhanusali, MD, opened with “Trending Topics in Skin of Color: What’s Hot, What’s Not!”, a review of viral TikTok content, quick-fix beauty claims, and procedure-related buzz circulating on social platforms. Their segment highlighted innovations steering treatment protocols forward, along with product categories earning growing confidence from dermatologists.

Attention then shifted to aesthetic medicine. Nada Elbuluk, MD, MSc, and Nkem Ugonabo, MD, MPH, guided viewers through complex questions linked to cosmetic interventions in patients with melanin-rich skin. Their presentation emphasized precision, safety, and realistic outcomes during an era when aesthetic content reaches audiences faster than peer-reviewed science.

Hair health took center stage next. Victoria Barbosa, MD, and Prince Adotama, MD, offered a concise overview of new research on pseudofolliculitis barbae, protective styles, and other concerns reported across diverse communities. Their segment underscored ongoing gaps in public awareness, along with advances providing new support for individuals seeking culturally competent guidance.

Sun exposure and cancer risk closed the official program. Rebecca Vasquez, MD, and Corey Hartman, MD, addressed persistent misconceptions regarding ultraviolet (UV) protection, along with data highlighting the recognition of skin cancer across tones previously considered at lower risk. Their discussion provided clarity on sunscreen use, diagnostic delays, and evolving public-health messaging.

 will extend coverage of Media Day with a focused interview on November 24 featuring Hartman, who currently serves as founder and medical director of Skin Wellness Dermatology in Birmingham, Alabama, and assistant clinical professor of Dermatology at the University of Alabama School of Medicine. His segment from Media Day will be discussed, with highlights including consumer confusion surrounding sunscreen ingredients, pigmentary concerns, and real-world challenges linked to daily photoprotection.

The upcoming podcast episode, scheduled for release on November 26, will revisit key themes from Media Day while offering additional commentary from Hartman on clinical priorities and key takeaways from his presentation from Media Day. Listeners can expect a nuanced look at prevention strategies, communication gaps in communities with richly pigmented skin, and future directions for education across media and clinical environments. The episode aims to anchor fast-moving conversations in evidence and experience, keeping pace with a growing demand for clear, trustworthy dermatologic guidance.

To learn more about SOCS’s mentorship programs and initiatives, visit 

Editor's note: This summary was edited with the help of AI tools.

Articles

The Skin of Color Society's 8th Annual Media Day provided a platform for expert insights on dermatology, health equity, and aesthetic medicine for patients with richly pigmented skin. The event featured discussions on trending topics, cosmetic interventions, hair health, and sun exposure risks, emphasizing evidence-based guidance amidst widespread misinformation. The program highlighted the importance of culturally competent care and addressed misconceptions about UV protection and skin cancer. A follow-up podcast will delve deeper into these themes, offering further expert commentary and practical advice for dermatology professionals.

Following the Skin of Color Society's (SOCS) 8th Annual Media Day, a Skin of Color Savvy podcast episode will be released highlighting the event.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Ronen Arai, MD, is a gastroenterologist with Baptist Health South Florida.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD

Gastroparesis, a chronic condition characterized by delayed gastric emptying, continues to place substantial strain on patients and healthcare systems. Following decades of inconsistent diagnostic approaches, scarce therapeutic choices, and mixed research findings, the American Gastroenterological Association (AGA) has introduced new guidelines designed to streamline management and highlight the significant evidence gaps that still need to be addressed.

Despite decades of clinical experience with the condition, the field continues to grapple with inconsistent diagnostic practices, limited therapeutic options, and a lack of high-quality data to guide care. The latest document offers 12 conditional recommendations for the diagnosis and management of gastroparesis, including use of 4-hour gastric emptying tests, use of metoclopramide or erythromycin as initial pharmacologic treatment, and shared patient-physician decision making for other treatment recommendations.

“I think one of the biggest issues is simply the diagnosis of gastroparesis, which can vary based on center or based on region of the country,” Ronen Arai, MD, a gastroenterologist with Baptist Health South Florida, said to 

. “That's a challenge, because it's hard to come up with a diagnosis that you can do studies on and be talking apples to apples and not have other diseases that you're throwing in there because the diagnosis was improperly made.”

Therapeutic limitations represent another major gap, with just 1 FDA-approved medication, metoclopramide, available. In the new guideline, the AGA conditionally recommends use of metoclopramide as well as erythromycin for first-line gastroparesis treatment.

“As a gastroenterologist being in practice for 25 years, those were around 25 years ago,” Arai said. “There's been a lot of other therapies that have come out, and they mentioned those in the guidelines, but none of them are really recommended as first-line treatment. It's frustrating that we haven't had any therapies that have been studied enough to warrant FDA approval.”

Among these mentioned therapies are domperidone, prucalopride, aprepitant, nortriptyline, buspirone, and cannabidiol, all of which are recommended against as first-line treatment for gastroparesis. Despite this, Arai notes that the guidelines open the door for shared decision making and potential use of these therapies in certain clinical situations.

The guidelines also address advanced interventions. While endoscopic options like G-POEM and certain surgical approaches are not recommended initially, they serve as important considerations for patients who fail medical management. Their inclusion provides clinicians with an updated framework for escalation of care, as these procedures were not mentioned in previous guidelines.

Ultimately, Arai emphasized the need for better-designed clinical trials using standardized diagnostic criteria. Improved consistency in diagnosing gastroparesis could strengthen future research, support therapeutic development, and expand meaningful options for patients living with this burdensome condition.

Editors’ note: Arai reports no relevant disclosures.

Brooks A. AGA Releases Gastroparesis Clinical Practice Guideline, Highlights Unmet Needs. HCPLive. September 19, 2025. Accessed November 21, 2025. 

https://www.hcplive.com/view/aga-releases-gastroparesis-clinical-practice-guideline-highlights-unmet-needs

Videos

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Nicole Koulov
Credit: McGovern Medical School

A study reported that an earlier onset of 

 between 4 to 6 months, along with greater severity and longer duration, was associated with a reduced likelihood of outgrowing 

“Food allergy and eczema often appear together in childhood, but scientists don’t fully understand how one condition affects the other,” said Nicole Koulov, second-year medical student at the University of Texas, in a statement.1 “Our findings highlight that eczema may play a role in shaping the development of oral tolerance to food allergens.”

A 2022 study reported that food allergies affect 30% of children with moderate and severe eczema, leading to symptoms of dry, cracked skin, rash, itchiness, ooziness, and crusted skin.

Koulov, an ACAAI member who worked with the FORWARD team under supervision of Mahboobeh Mahdavinia, MD, PhD, on this project, presented these findings in the poster, “Association Between Clinical Features Of Eczema And Outgrowing Of Food Allergies In Pediatric Patients,” at the 

2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting 

in Orlando, Florida, from November 6 – 10.

The FORWARD multicenter prospective cohort study included 855 children aged 0 – 12 years with a history of outgrown IgE-mediated food allergies, reported by caregivers via surveys. Investigators assessed the presence and duration of eczema using questionnaires, which captured the timing of onset and remission. A survey on skin distribution and cumulative therapies needed to treat eczema assessed eczema severity.

Generalized additive models revealed a significant non-linear association between eczema duration and food allergy resolution (

 <.006). The predicted probability of outgrowing an allergy was lowest at shorter eczema durations, increased modestly for durations of 8–10 years, and then declined again. Greater eczema severity was linked to lower odds of outgrowing a food allergy (

The study also revealed that children who developed eczema at 4 – 6 months, compared to 0 – 3 months, had significantly lower odds of food allergy resolution (

The researchers noted that, although eczema does not directly cause food allergies, the interaction between skin barrier integrity, immune function, and allergen exposure may help explain why some children outgrow their allergies while others do not.

“These findings show that eczema is more than just a coexisting condition – it may directly influence whether children overcome food allergies,” said allergist Amal Assa’ad, MD, co-author of the study and ACAAI member,” in a statement. “Our data suggest that the timing and management of eczema could be an important factor in helping children develop tolerance.”

This adds to previous FORWARD findings that discovered eczema onset before 4 months correlated with a greater number of food allergies (odds ratio [OR], 1.14, 95% CI: 1.02-1.28) compared to eczema onset after 12 months.

 Eczema onset in children with a food allergy was particularly earlier than in the general population.

FORWARD provides further insight into the link between food allergies and eczema. Last year, 

 reported a study with > 8000 pediatric patients from the Pediatric Eczema Elective Registry found that certain food allergies are associated with uncontrolled atopic dermatitis and long-term atopic dermatitis persistence.4 These associations were pronounced in subgroup analyses of milk (adjusted odds ratio [aOR], 1.46), egg (aOR, 1.49), and peanut allergies (aOR, 1.50).

“The observed relationship between food allergy and AD persistence suggests that food allergy is an important prognostic factor for long-term AD outcomes,” wrote investigators of the 2024 study.

Study finds link between eczema patterns and children’s ability to outgrow food allergies. EurekAlert! Published November 6, 2025. 

https://www.eurekalert.org/news-releases/1103483

Mehta Y, Fulmali DG. Relationship Between Atopic Dermatitis and Food Allergy in Children. Cureus. 2022 Dec 31;14(12):e33160. 

Hikma Abbas H, Mahdavinia M, Jiang J, et al. The age of eczema onset increases the risk of multiple food allergies. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2023.11.030

Brooks A. Pediatric Food Allergies Linked to Uncontrolled Atopic Dermatitis, Long-Term Prognosis. HCPLive. December 18, 2025. 

https://www.hcplive.com/view/pediatric-food-allergies-linked-uncontrolled-atopic-dermatitis-long-term-prognosis

A study highlights the relationship between eczema onset and the likelihood of outgrowing food allergies in children. Earlier onset of eczema, particularly between 4 to 6 months, along with greater severity and longer duration, is linked to reduced chances of overcoming food allergies. The research suggests that eczema may influence the development of oral tolerance to food allergens. The study also emphasizes the importance of eczema management in potentially aiding children to develop tolerance to food allergens, providing insights into the complex interaction between skin barrier integrity, immune function, and allergen exposure.

Study finds eczema onset at 4–6 months, greater severity, and longer duration linked to lower odds of outgrowing food allergies in children.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Eczema Onset at 4 Months May Reduce the Chance of Outgrowing Food Allergies

Ixekizumab (IXE) delivers more durable high-level skin clearance among patients with 

 than several other commonly used biologic drugs, new-real world data suggest.

These data were authored by such investigators as Andreas Pinter, MD, PhD, from the Department of Dermatology at the University Hospital Frankfurt am Main in Germany. The findings were presented in a poster session at the 

2025 Fall Clinical Dermatology Conference

Despite the variety of biologic agents targeting the various inflammatory pathways in psoriasis, Pinter and coauthors pointed to the prior lack of long-term, real-world comparative data. They noted this to be particularly true data on the durability of high-level skin clearance in such patients.

To address the limited level of research on this, the investigative team carried out Psoriasis Study of Health Outcomes (PSoHO) study as a 36-month, non-interventional, international cohort study. They looked into the long-term efficacy of commonly used biologic agents in routine clinical practice settings, involving 1981 adult subjects residing in 23 countries. The team also looked at a European Medicines Agency (EMA) on-label sub-population in their research.

In this particular analysis, Pinter et al focused on the most recent pre-specified endpoints: the durability of Psoriasis Area and Severity Index (PASI)100 and PASI90 responses among subjects. The investigators defined durability as attainment, at the 12-week mark, of PASI100 or PASI90 and maintaining that response at the 6, 12, 18, and 24-month marks.

Confounding variables such as drug cessation, treatment switching, and baseline differences were taken into account by Pinter and coauthors via their use of marginal structural models (MSM). These models generated adjusted odds ratios (ORs) with 95% confidence intervals for IXE compared with tildrakizumab (TILD), secukinumab (SEC), risankizumab (RIS), adalimumab (ADA), guselkumab (GUS), and ustekinumab (UST).

Outcomes were reported both with non-responder imputation (NRI) and as observed. In Pinter and colleagues' adjusted analysis of the overall population, they found IXE demonstrated increased odds of attaining and sustaining PASI90 and PASI100 responses as opposed to SEC, TILD, GUS, ADA, and UST. When compared with RIS, IXE was shown by Pinter and coauthors to have similar odds of durability for both PASI90 and PASI100.

They pointed to comparable long-term performance between these interleukin (IL)-17 and IL-23 pathway inhibitors. The study's European Medicines Agency (EMA) on-label subgroup yielded largely consistent findings with those of the overall population. However, a single distinction did come about for PASI100 durability. Specifically, the investigators found in this subgroup, patients being given IXE were found to have significantly greater odds of maintaining complete skin clearance as opposed to patients treated with RIS.

Additionally, results were shown to be comparable to those of patients receiving SEC. The PSoHO data emphasized the clinical relevance of durability as a central therapeutic aim in the management of psoriasis. Prior data, Pinter et al noted, has demonstrated that individuals who attain a PASI100 score earlier accumulate more days with minimal impact on quality of life, as measured by DLQI scores of 0 or 1. Consequently, they added, durability not only suggests biologic efficacy but also translates into meaningful patient-centered outcomes.

Aligning with many long-term observational cohorts, the PSoHO study faced potential bias related to switching between treatments. Drug switching may be impacted by disease severity, treatment access, comorbid psoriatic arthritis, costs of medication, or response levels. The implementation of MSM was intended to address such sources of confounders and strengthen the validity of comparative findings.

For any further information on topics such as these, view the latest coverage of the 

Pinter A, Brnabic A, Maul JT, et al. Comparative Durability of Biologics for Patients With Moderate-to-Severe Psoriasis Adjusted for Drug Switching Over Time: 24-Month Outcomes From the International Observational Psoriasis Study of Health Outcomes (PSoHO). Poster presented at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Yu N, Wang Y, Cui L, et al. Comprehensive analysis of effectiveness and cost‐effectiveness of treatments for psoriasis integrating clinician‐ and patient‐reported outcomes: A cohort study from speech. Dermatologic Therapy. 2025;2025(1). doi:10.1155/dth/9464860. 

Ixekizumab (IXE) has shown superior durability in achieving high-level skin clearance in psoriasis patients compared to several other biologics, according to recent real-world data. The Psoriasis Study of Health Outcomes (PSoHO) assessed the long-term efficacy of biologics in a 36-month international cohort study involving 1981 adults. IXE demonstrated increased odds of maintaining PASI90 and PASI100 responses compared to secukinumab, tildrakizumab, guselkumab, adalimumab, and ustekinumab. The study highlighted the importance of durability in psoriasis management, linking it to improved patient-centered outcomes and quality of life.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Credit: PRIME Continuing Medical Education

A phase 2B trial supports rezpegaldesleukin, an IL-2 receptor pathway agonist, for the treatment of 

. James Treat, MD, from Children’s Hospital of Philadelphia, presented the 16-week induction therapy findings from the REZOLVE-AD as a late breaker at the 

2025 American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting

 in Orlando, Florida, on Saturday, November 8.

“Given that approximately one in four patients with atopic dermatitis also have asthma, improving asthma symptoms is a significant consideration in clinical treatment decisions," said lead author Jonathan Corren, MD, an associate clinical professor of medicine and pediatrics at the David Geffen School of Medicine at the University of California, in a statement.

 "The results with rezpegaldesleukin in patients with atopic dermatitis and comorbid asthma demonstrate that promotion of Treg activity may also have benefits to the lower airways, an observation which warrants further investigation."

Rezpegaldesleukin offers a novel therapeutic approach for treating AD and asthma, selectively expanding the function of regulatory T-cells. The US Food & Drug Administration (FDA) granted Nektar Therapeutics the Fast Track Designation for rezpegaldesleukin to treat moderate-to-severe atopic dermatitis in adults and children ≥ 12 years who are not adequately controlled with topical prescription therapies.

REZOLVE-AD, a randomized, double-blind, placebo-controlled, multicenter phase 2b trial, evaluated rezpegaldesleukin in 393 adults with moderate-to-severe AD.

 Participants were randomized 3:3:3:2 to receive subcutaneous rezpegaldesleukin 24 μg/kg every 2 weeks (n = 104), 18 μg/kg every 2 weeks (n = 106), 24 μg/kg every 4 weeks (n = 110), or placebo (n = 73).

The study assessed AD severity using the Eczema Area and Severity Index (EASI), validated Investigator Global Assessment (vIGA-AD), and Numerical Rating Scale Itch (NRS-Itch). Investigators also collected the Asthma Control Questionnaire-5 (ACQ-5) at baseline and week 16 from patients with asthma (n = 99), including 25 with uncontrolled asthma (baseline ACQ-5 ≥1.5).

Rezpegaldesleukin 24 μg/kg every 2 weeks brought significant improvements in mean percent change in EASI (

 <.05), NRS-Itch response (≥4-point reduction) (

 <0.01) at Week 16, compared with placebo. Corren and colleagues observed improvements across baseline characteristics, including disease severity, sex, region, and asthma comorbidity.

Among patients with a history of asthma, patients experienced a reduction in ACQ-5 scores with all 3 rezpegaldesleukin doses at week 16, though only the 24 μg/kg every 2 or 4 weeks achieved statistical significance compared to placebo (P <.05). The study showed more pronounced improvements in patients with only partially controlled or uncontrolled asthma.

In total, 75% of patients with uncontrolled asthma at baseline experienced clinically significant improvement with rezpegaldesleukin. Among patients with a baseline ACQ-5 of ≥ 0.5 (n = 53), at least half of them experienced clinically significant improvement, indicated by a ≥ 0.5-point reduction in ACQ-5 at week 16.

At ACAAI, Treat also presented crossover data, including 42 placebo patients who crossed over at week 16 and continued in the study on a treatment escape arm to receive high-dose rezpegaldesleukin 24 µg/kg every 2 weeks. At crossover week 24, 60% had an EASI-75 response, 33% had vIGA-AD 0/1 response, 37% had an EASI-90 response, and 50% had an Itch NRS response.

This data supports rezpegaldesleukin 24 μg/kg every 2 weeks with a 24-week treatment induction period. The trial observed no new safety signals.

“These observations of improvement in asthma control in REZOLVE-AD support the broad potential of rezpegaldesleukin's Treg mechanism across multiple T-cell mediated inflammatory diseases," said Jonathan Zalevsky, PhD, chief research and development officer of Nektar, in a statement.

 "The data demonstrate that rezpegaldesleukin could offer a unique and differentiated innovative treatment for atopic dermatitis, particularly as these findings have not been observed with other biologic mechanisms recently approved or in advanced development.”

Corren J, Lio P, Silverberg J, et al. REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL. 

doi:https://doi.org/10.1016/j.anai.2025.10.021

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting. Nektar Therapeutics. November 8, 2025. 

https://ir.nektar.com/news-releases/news-release-details/new-data-rezolve-ad-study-rezpegaldesleukin-presented-late

Rezpegaldesleukin, an IL-2 receptor pathway agonist, shows promise in treating atopic dermatitis (AD) and asthma, as demonstrated in a phase 2B trial. The trial, REZOLVE-AD, evaluated its efficacy in 393 adults with moderate-to-severe AD, revealing significant improvements in AD severity and asthma control, particularly in patients with uncontrolled asthma. The FDA has granted Fast Track Designation for rezpegaldesleukin for moderate-to-severe AD in patients aged 12 and older. The trial's findings suggest potential benefits of Treg activity promotion in treating T-cell mediated inflammatory diseases.

Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma

Julia Grapsa, MD, PhD, is the director for education in echocardiography at Brigham and Women's Hospital and a faculty member at Harvard Medical School.

Grapsa highlights the significant treatment gap between men and women suffering from aortic stenosis, as well as the skewed mortality risks resulting from them.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Addressing Disparities in Aortic Stenosis Care for Women, With Julia Grapsa, MD, PhD

John Gill, MD, is a professor of medicine with tenure at the University of British Columbia, Division of Nephrology, Saint Paul's Hospital.

Gill describes tegoprubart’s efficacy and safety for post-kidney transplant immunosuppression and reviews key phase 2 BESTOW trial data from ASN.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Innovation in Transplant Immunosuppression With Tegoprubart, With John Gill, MD

Podcasts

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Phase 3 Data on Telitacicept in IgA Nephropathy at ASN Kidney Week 2025

Shyam Joshi, MD, examines the evolving role of BTK inhibition, particularly remibrutinib, in the treatment algorithm for chronic spontaneous urticaria.

Video Series

 Leveraging BTKi in CSU Management

Shyam Joshi, MD, reviews fundamental updates in the management of chronic spontaneous urticaria.

Updates in Chronic Spontaneous Urticaria Management

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Jürgen Floege, MD, senior professor at RWTH Aachen University’s Medical School

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.


Post Conference Perspectives

PREVAIL: Felzartamab’s Sustained Clinical Outcomes In IgAN, With Jurgen Floege, MD

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

Alopecia

Mid Trial Update Released on Baricitinib for Frontal Fibrosing Alopecia

Michael Manning, MD: An allergy, asthma, & immunology specialist located in Arizona

At ACAAI 2025, Manning highlighted sustained attack reduction and strong patient preference for donidalorsen across long-term and switch data.

Donidalorsen Shows Durable Long-Term Efficacy for HAE, With Michael Manning, MD

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

Latest News

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD

Eczema Onset at 4 Months May Reduce the Chance of Outgrowing Food Allergies

Durability of Biologics for Psoriasis Compared, Adjusted for Drug Switching Over Time

Rezpegaldesleukin Shows Strong Phase 2b Results for Atopic Dermatitis, Asthma